Avastin and Malignant Gliomas

Book Series: Controversies in Neuro-Oncology

Volume 1


Thomas C. Chen, Marc Chamberlain

DOI: 10.2174/97816080513281100101
eISBN: 978-1-60805-132-8, 2010
ISBN: 978-1-60805-519-7
ISSN: 2210-5565 (Print)

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-...[view complete introduction]
US $
Buy Personal Book
Order Library Book
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Bevacizumab with Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

- Pp. 19-23 (5)

Fabio M. Iwamoto and Philip H. Gutin


<p>Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), recently received accelerated approval by the US Federal and Drug Adminstration as single-agent for recurrent glioblastomas (GBM). Preclinical studies suggest that inhibition of VEGF and radiotherapy (RT) have a synergistic effect in gliomas. We recently conducted a pilot study of bevacizumab and hypo-fractionated stereotactic RT for patients with recurrent GBM and anaplastic gliomas (AG). Patients received bevacizumab (10 mg/kg IV) every 2 weeks of 28-day cycle and 30 Gy of hypofractionated stereotactic RT in 5 fractions after the first cycle of bevacizumab. Twenty-five patients (20 GBM and 5 AG) were included. For the GBM cohort, overall response rate was 50%, 6-month progression free survival was 65% and median overall survival was 12.5 months. Bevacizumab with hypofractionated RT is an active regimen in malignant gliomas and is currently being studied in newly-diagnosed glioblastomas in combination with temozolomide.</p>

Purchase Chapter  Book Details


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science